Truncated Peptide Libraries

One of many convenient PepSet™ Peptide Library designs, the Truncated Library’s key focus is to identify the shortest active peptide sequence.

Especially useful in epitope mapping, a series of short peptides decreasing in length is produced by systematically removing the sequence’s flanking residues.

These peptide libraries are fully customisable, with modifications and endings to optimise efficiency. Even the direction of truncation can be chosen according to known essential residues.

T-Cell Truncated Peptide Libraries

A version of truncation specific for T-cell epitope mapping, T-Cell Truncated Peptide Libraries test all possible epitopes over the protein of interest.

It is known that peptides of 8-11 residues partially comprise the epitopes of cytotoxic T lymphocytes. With this knowledge, sets of progressively truncated homologous peptides are grouped together for testing. After screening, positive results can be further broken down to identify individual epitopes, saving time and resources.

Epitope Mapping with Peptide Libraries

With Mimotopes’ multipin synthesis system, hundreds of peptides can be produced simultaneously. These high quality peptide libraries are ideal tools for epitope mapping and for the rapid identification of:

  • T-Cells
  • T-Cell clones
  • T-Helper Cell clones
  • T-Cell lines
  • Unpurified T-cells (such as lymph node cells and peripheral blood mononuclear cells, PBMC)

Contact us today for a peptide quote! 

Australia

☎ +61 3 9565 1111

✉ australia@mimotopes.com

North and South America 

☎ +1 651 603 0909

✉ useast@mimotopes.com
     uswest@mimotopes.com

asia

☎ +61 3 9565 1111

✉ asia@mimotopes.com

UK / Europe / Africa / Middle East

☎ +44 (0)151 556 0547

✉ europe@mimotopes.com

Contact us today for a peptide quote! 

Australia

☎ +61 3 9565 1111

australia@mimotopes.com

North and South America 

☎ +1 651 603 0909

  ✉ useast@mimotopes.com 
  ✉ uswest@mimotopes.com

asia

☎ +61 3 9565 1111

✉ asia@mimotopes.com

UK/ Europe/ Africa/ Middle East

☎ +44 (0)151 556 0547

✉ europe@mimotopes.com

Go to article: Home | Pause for thoughtGo to article: In this issueGo to article: NSFGo to article: ContentsGo to article: Datwyler Company Insight Go to article: DatwylerGo to article: NewsGo to article: BaxterGo to article: Covid-19 executive briefing by GlobalDataGo to article: ELPRO Monitoring SolutionsGo to article: Abivax’s ABX464 enticing in theory for Covid-19 but mechanism, trial design issues belie potential for successGo to article: Abiomed’s Impella receives FDA Emergency Use Authorization during Covid-19Go to article: FargoGo to article: Disruptions to global oncology trials have fallen to a three-month lowGo to article: MimotopesGo to article: AstraZeneca/Oxford University and CanSino publish promising Covid-19 vaccine cliGo to article: Biotech IPO valuation relies on data to enter capital markets during Covid-19 paGo to article: Nelson LabsGo to article: The pharma industry briefingGo to article: Pfeiffer VacuumGo to article: A century of cultures: celebrating the world’s oldest lab culture collectionGo to article: SkyepharmaGo to article: Gut feeling: exploring the therapeutic potential of the gut-brain axisGo to article: OptelGo to article: Crabby concoctions: why pharma’s thirst for crustacean blood is up for debateGo to article: Air FranceGo to article: Debunking myths about puberty blockers for transgender childrenGo to article: MicronovaGo to article: Hiring from home: pharma recruitment in the age of Covid-19 Go to article: Nipro PharmapackagingGo to article: Q&A: breaking new ground in pharma packaging with HoneywellGo to article: WipotecGo to article: Treatment-resistant rare diseases: exploring landmark drug approvals in 2020Go to article: VEGA Company Insight Go to article: VEGA AustraliaGo to article: Modernising pharma patents: can AI be an inventor?Go to article: ILC Dover Go to article: Boosting agility to accelerate project timescales Go to article: Scandinavian HealthGo to article: Doing the right thing: the enhanced case for complianceGo to article: Deals in brief powered by GlobalDataGo to article: The key list powered by GlobalDataGo to article: Global markets and indices powered by GlobalDataGo to article: Macro-economic indicators (1 of 2) powered by GlobalDataGo to article: Macro-economic indicators (2 of 2) powered by GlobalDataGo to article: EventsGo to article: Next issue